A Study of IBI3032 in Chinese Participants With Overweight or Obesity
Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.